FDA removes clinical hold on Entrada’s Duchenne therapy
Entrada plans to initiate the Phase Ib study of ENTR-601-44 in the US in the first half of next year.
Drug Development
AstraZeneca’s Imfinzi bladder cancer regimen improves survival in Phase III trial
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
Allakos cuts 75% of workforce after chronic hives trial failure
JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole
Samsung Biologics and LigaChem extend ADC services deal
Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease
